Previous 10 | Next 10 |
EVO/EVO+ VISIAN® Implantable Collamer® Lens for Myopia, and EVO/EVO+ VISIAN® Toric Implantable Collamer® Lens for Myopia with Astigmatism Additional Study Recommendations and Considerations to be Addressed STAAR Surgical Company (NASDAQ: STAA), a leading devel...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 117 weeks of public selections as part of this ongoing live forward-testing. ...
Gainers: TCF Financial (NYSE: TCF ) +99% . Myriad Genetics (NASDAQ: MYGN ) +52% . SunPower (NASDAQ: SPWR ) +33% . the Rubicon Project (NYSE: RUBI ) +31% . Vanda Pharmaceuticals (NASDAQ: VNDA ) +29% . NIC (NASDAQ: EGOV ) +24% . TCR2 Therapeutics (NASDAQ: TCRR ) ...
STAAR Surgical ( STAA +19.7% ) is up almost 70% higher volume following its release of better-than-expected Q2 results after the close yesterday. Key items: More news on: STAAR Surgical Company, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ......
STAAR Surgical Company (STAA) Q2 2019 Earnings Conference Call July 31, 2019 16:30 ET Company Participants Brian Moore - Investor Relations Caren Mason - President and Chief Executive Officer Deborah Andrews - Chief Financial Officer Conference Call Participants Chris Coole...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the submission of its multi-site European pivotal clinical trial data for the EVO+ Visian® ICL with Aspheric (EDOF) Opti...
STAAR Surgical (NASDAQ: STAA ): Q2 Non-GAAP EPS of $0.14 beats by $0.04 ; GAAP EPS of $0.08 beats by $0.04 . More news on: STAAR Surgical Company, Earnings news and commentary, Consumer stocks news, Read more ...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended June 28, 2019. Second Quarter 2019 Overview Net Sales of $39.7 Mi...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended June 28, 2019 on Wednesday, July 31, 2019 after t...
STAAR Surgical Company (STAA) has a 30-year history specializing in products for ophthalmic surgery and vision correction; first, for the treatment of cataracts going back to 1991, and the introduction of its revolutionary 'implantable contact lenses' marketed as Visian ICL in 1996. The stock ...
News, Short Squeeze, Breakout and More Instantly...
STAAR Surgical Company Company Name:
STAA Stock Symbol:
NASDAQ Market:
STAAR Surgical Company Website:
2024-07-14 17:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Will...
2024-05-24 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...